Chamath Palihapitiya Reenters SPAC Market: Previous 18 Deals Show Average Loss of 14%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Should l Buy CLOV?
Source: Benzinga
New SPAC Launch: Chamath Palihapitiya has filed for a new SPAC, American Exceptionalism Acquisition Corp A (ticker AEAC), aiming to raise $250 million and invest in sectors like AI, clean energy, U.S. defense, or decentralized finance.
Investor Sentiment: Despite launching the new SPAC, investor sentiment remains cautious due to poor past returns from his previous SPAC deals, with a recent poll indicating that 70.7% of respondents were against him launching another SPAC.
Performance Overview: Palihapitiya has been involved in 18 SPACs, with an average return of -13.98%. His own SPACs have performed worse, averaging -26.24%, while PIPE deals he financed yielded a modest +1.34%.
Future Prospects: The new SPAC's structure includes milestone-based vesting for founder shares, which may encourage long-term investment. However, given past performance, interest from investors might be limited despite Palihapitiya's connections in Silicon Valley and the White House.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLOV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLOV
Wall Street analysts forecast CLOV stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.190
Low
3.00
Averages
3.35
High
3.70
Current: 2.190
Low
3.00
Averages
3.35
High
3.70
About CLOV
Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Surprise Increase in Medicare Advantage Payment Rates Boosts Healthcare Stocks
- Medicare Payment Rate Increase: The government unexpectedly raised payment rates for Medicare Advantage plans, increasing the federal funds received per patient by insurance companies, which is projected to enhance profit margins for major providers like UnitedHealth and Humana.
- Alignment Healthcare Stock Surge: Alignment Healthcare (NASDAQ:ALHC) shares jumped 18.7%, reflecting a strong market reaction to the company's outlook, with 26 moves greater than 5% in the past year indicating significant market perception shifts due to this news.
- Market Rally: The increase in Medicare payment rates boosted overall market confidence, leading to significant gains in major indices like the S&P 500 and Dow Jones Industrial Average, which in turn spurred widespread buying activity in major healthcare stocks.
- Investment Return Analysis: Alignment Healthcare has risen 9.3% since the beginning of the year, trading at $22.11, close to its 52-week high of $23.81 from January 2026, with a five-year investment of $1,000 now worth $1,016, demonstrating its long-term investment value.
See More
Clover Health Partners with HealthEx to Enhance Healthcare Data Interoperability
- Data Interoperability Partnership: Clover Health's new collaboration with HealthEx enables Medicare Advantage members to securely access and share clinical records and claims data, further advancing patients' rights to their health data, which is central to federal interoperability efforts.
- Streamlined User Experience: Through HealthEx, Clover members can verify their identity and authorize access to their records, simplifying the process of retrieving clinical records and claims data, thus enhancing user experience and satisfaction by eliminating the need for multiple portal logins.
- Infrastructure Expansion: This collaboration builds on the interoperability infrastructure powered by Counterpart Health, which not only supports Clover Health's data exchange but also provides scalable interoperability capabilities for other health plans, fostering collaboration across the healthcare ecosystem.
- Patient-Directed Health Management: Clover Health empowers members to access their health records more comprehensively through this functionality, granting patients control over their health information and demonstrating how member-directed access can be implemented in practice.
See More
Surge in Options Trading Volume for Enovix and Clover Health
- Enovix Options Volume: Enovix Corp saw options trading volume of 47,349 contracts, equivalent to approximately 4.7 million shares, representing about 85% of its average daily trading volume of 5.6 million shares over the past month, indicating heightened market interest in its future performance.
- High-Frequency Trading: Notably, the $7 strike call option expiring on October 16, 2026, has seen 11,736 contracts traded today, representing around 1.2 million underlying shares, suggesting increased investor expectations for Enovix's stock price appreciation.
- Clover Options Activity: Clover Health Investments Corp recorded options trading volume of 45,122 contracts, approximately 4.5 million shares, which accounts for about 80% of its average daily trading volume of 5.6 million shares over the past month, reflecting active market interest in its stock.
- Clover High-Frequency Trading: The $2 strike call option expiring on April 10, 2026, has seen 13,076 contracts traded today, representing about 1.3 million underlying shares, indicating optimistic sentiment among investors regarding Clover's future performance.
See More
Advertising Stocks Surge, Led by Advantage Solutions
- Advertising Sector Uptrend: Advertising stocks collectively rose by approximately 2.5% on Monday, indicating a renewed market confidence in the sector, which may reflect expectations of increased advertising spending and subsequently boost related companies' performance.
- Advantage Solutions Leads: Advantage Solutions saw its stock price surge by about 9.7%, positioning it as the leader among advertising stocks, suggesting investor optimism regarding its future growth potential, possibly linked to recent business expansions or new client acquisition strategies.
- National CineMedia Strong Performance: National CineMedia's stock increased by approximately 6.5%, reflecting market confidence in its cinema advertising segment, likely benefiting from the recovery of the film industry and the return of audiences to theaters, which could enhance advertising revenues.
- Positive Industry Outlook: The robust performance of advertising stocks may signal overall economic recovery, with investors maintaining an optimistic view on increased advertising expenditures, which will likely enhance the profitability and market valuations of related companies.
See More
Clover Health CFO Resignation and Interim Appointment Announced
- Executive Change: Clover Health announced that CFO Peter Kuipers will resign effective March 30, 2026, while remaining in an advisory role until April 24, 2026, to ensure a smooth transition in financial management.
- Interim Appointment: The Board has appointed Clay Thornton, the current CFO of Clover’s insurance plan, as interim CFO effective immediately, aimed at maintaining financial stability during the executive transition.
- Market Reaction: Clover Health's stock rose 1.136% in premarket trading to $1.78, reflecting investor confidence in the company's future despite potential short-term uncertainties associated with the executive change.
- Future Outlook: Clover Health expects a 46% membership growth and its first full year of GAAP profitability in 2026, indicating positive progress in improving financial performance and market positioning.
See More
Clover Health CFO Peter Kuipers Steps Down, Clay Thornton Appointed Interim
- Executive Transition: Clover Health's CFO Peter Kuipers stepped down on March 30, 2026, but will remain as an advisor until April 24, ensuring a smooth transition and indicating stability during executive changes.
- Interim Appointment: The Board appointed Clay Thornton, the current CFO of Clover's insurance plan, as Interim CFO effective immediately, reflecting the company's trust in his extensive experience in Medicare Advantage.
- Financial Guidance Reaffirmed: Clover Health reiterated its financial guidance for fiscal year 2026, emphasizing its commitment to sustainable profitability and market growth, which reflects confidence in future performance.
- Leadership Support: CEO Andrew Toy expressed gratitude for Kuipers' contributions and highlighted Thornton's leadership and industry experience, which will aid the company's success in the next phase, showcasing a positive outlook for future developments.
See More
Surprise Increase in Medicare Advantage Payment Rates Boosts Healthcare Stocks
- Medicare Payment Rate Increase: The government unexpectedly raised payment rates for Medicare Advantage plans, increasing the federal funds received per patient by insurance companies, which is projected to enhance profit margins for major providers like UnitedHealth and Humana.
- Alignment Healthcare Stock Surge: Alignment Healthcare (NASDAQ:ALHC) shares jumped 18.7%, reflecting a strong market reaction to the company's outlook, with 26 moves greater than 5% in the past year indicating significant market perception shifts due to this news.
- Market Rally: The increase in Medicare payment rates boosted overall market confidence, leading to significant gains in major indices like the S&P 500 and Dow Jones Industrial Average, which in turn spurred widespread buying activity in major healthcare stocks.
- Investment Return Analysis: Alignment Healthcare has risen 9.3% since the beginning of the year, trading at $22.11, close to its 52-week high of $23.81 from January 2026, with a five-year investment of $1,000 now worth $1,016, demonstrating its long-term investment value.
See More
Clover Health Partners with HealthEx to Enhance Healthcare Data Interoperability
- Data Interoperability Partnership: Clover Health's new collaboration with HealthEx enables Medicare Advantage members to securely access and share clinical records and claims data, further advancing patients' rights to their health data, which is central to federal interoperability efforts.
- Streamlined User Experience: Through HealthEx, Clover members can verify their identity and authorize access to their records, simplifying the process of retrieving clinical records and claims data, thus enhancing user experience and satisfaction by eliminating the need for multiple portal logins.
- Infrastructure Expansion: This collaboration builds on the interoperability infrastructure powered by Counterpart Health, which not only supports Clover Health's data exchange but also provides scalable interoperability capabilities for other health plans, fostering collaboration across the healthcare ecosystem.
- Patient-Directed Health Management: Clover Health empowers members to access their health records more comprehensively through this functionality, granting patients control over their health information and demonstrating how member-directed access can be implemented in practice.
See More
Surge in Options Trading Volume for Enovix and Clover Health
- Enovix Options Volume: Enovix Corp saw options trading volume of 47,349 contracts, equivalent to approximately 4.7 million shares, representing about 85% of its average daily trading volume of 5.6 million shares over the past month, indicating heightened market interest in its future performance.
- High-Frequency Trading: Notably, the $7 strike call option expiring on October 16, 2026, has seen 11,736 contracts traded today, representing around 1.2 million underlying shares, suggesting increased investor expectations for Enovix's stock price appreciation.
- Clover Options Activity: Clover Health Investments Corp recorded options trading volume of 45,122 contracts, approximately 4.5 million shares, which accounts for about 80% of its average daily trading volume of 5.6 million shares over the past month, reflecting active market interest in its stock.
- Clover High-Frequency Trading: The $2 strike call option expiring on April 10, 2026, has seen 13,076 contracts traded today, representing about 1.3 million underlying shares, indicating optimistic sentiment among investors regarding Clover's future performance.
See More
Advertising Stocks Surge, Led by Advantage Solutions
- Advertising Sector Uptrend: Advertising stocks collectively rose by approximately 2.5% on Monday, indicating a renewed market confidence in the sector, which may reflect expectations of increased advertising spending and subsequently boost related companies' performance.
- Advantage Solutions Leads: Advantage Solutions saw its stock price surge by about 9.7%, positioning it as the leader among advertising stocks, suggesting investor optimism regarding its future growth potential, possibly linked to recent business expansions or new client acquisition strategies.
- National CineMedia Strong Performance: National CineMedia's stock increased by approximately 6.5%, reflecting market confidence in its cinema advertising segment, likely benefiting from the recovery of the film industry and the return of audiences to theaters, which could enhance advertising revenues.
- Positive Industry Outlook: The robust performance of advertising stocks may signal overall economic recovery, with investors maintaining an optimistic view on increased advertising expenditures, which will likely enhance the profitability and market valuations of related companies.
See More
Clover Health CFO Resignation and Interim Appointment Announced
- Executive Change: Clover Health announced that CFO Peter Kuipers will resign effective March 30, 2026, while remaining in an advisory role until April 24, 2026, to ensure a smooth transition in financial management.
- Interim Appointment: The Board has appointed Clay Thornton, the current CFO of Clover’s insurance plan, as interim CFO effective immediately, aimed at maintaining financial stability during the executive transition.
- Market Reaction: Clover Health's stock rose 1.136% in premarket trading to $1.78, reflecting investor confidence in the company's future despite potential short-term uncertainties associated with the executive change.
- Future Outlook: Clover Health expects a 46% membership growth and its first full year of GAAP profitability in 2026, indicating positive progress in improving financial performance and market positioning.
See More
Clover Health CFO Peter Kuipers Steps Down, Clay Thornton Appointed Interim
- Executive Transition: Clover Health's CFO Peter Kuipers stepped down on March 30, 2026, but will remain as an advisor until April 24, ensuring a smooth transition and indicating stability during executive changes.
- Interim Appointment: The Board appointed Clay Thornton, the current CFO of Clover's insurance plan, as Interim CFO effective immediately, reflecting the company's trust in his extensive experience in Medicare Advantage.
- Financial Guidance Reaffirmed: Clover Health reiterated its financial guidance for fiscal year 2026, emphasizing its commitment to sustainable profitability and market growth, which reflects confidence in future performance.
- Leadership Support: CEO Andrew Toy expressed gratitude for Kuipers' contributions and highlighted Thornton's leadership and industry experience, which will aid the company's success in the next phase, showcasing a positive outlook for future developments.
See More
